Journal article
Kava for the treatment of generalized anxiety disorder RCT: Analysis of adverse reactions, liver function, addiction, and sexual effects
J Sarris, C Stough, R Teschke, ZT Wahid, CA Bousman, G Murray, KM Savage, P Mouatt, C Ng, I Schweitzer
Phytotherapy Research | Published : 2013
DOI: 10.1002/ptr.4916
Abstract
Presently, little is known about a number issues concerning kava (Piper methysticum), including (i) whether kava has any withdrawal or addictive effects; (ii) if genetic polymorphisms of the cytochrome (CYP) P450 2D6 liver enzyme moderates any potential adverse effects; and (iii) if medicinal application of kava has any negative or beneficial effect on sexual function and experience. The study design was a 6-week, double-blind, randomized controlled trial (n = 75) involving chronic administration of kava (one tablet of kava twice per day; 120 mg of kavalactones per day, titrated in non-response to two tablets of kava twice per day; 240 mg of kavalactones) or placebo for participants with gen..
View full abstractRelated Projects (1)
Grants
Awarded by Australian National Health and Medical Research Council fellowship (NHMRC)
Awarded by NHMRC
Funding Acknowledgements
Sincere thanks are extended to Justine Lomas for assistance with the study randomization, and to Samantha Hollis and Vi Tran for data entry. Dr Jerome Sarris is funded by an Australian National Health and Medical Research Council fellowship (NHMRC funding ID 628875), in a strategic partnership with The University of Melbourne, NICM Collaborative Research Centre in Neurocognition, and The Centre for Human Psychopharmacology at Swinburne University of Technology. Dr Chad Bousman is funded by a University of Melbourne John McKenzie Fellowship. The study was funded by Integria Healthcare and the NHMRC (ID 628875).